pembrolizumab {reportRmd}

Survival data Survival status and ctDNA levels for patients receiving pembrolizumab

Description

Survival data

Survival status and ctDNA levels for patients receiving pembrolizumab

Usage

pembrolizumab

Format

A data frame with 94 rows and 15 variables:

id

Patient ID

age

Age at study entry

sex

Patient Sex

cohort

Study Cohort: A = Squamous cell carcinoma of soft pallate, B = Triple negative breast cancer, C = Ovarian, high grade serous, D = Melanoma, E = Other Solid Tumor

l_size

Target lesion size at baseline

pdl1

PD L1 percent

tmb

log of TMB

baseline_ctdna

Baseline ctDNA

change_ctdna_group

Did ctDNA increase or decrease from baseline to cycle 3

orr

Objective Response

cbr

Clinical Beneficial Response

os_status

Overall survival status, 0 = alive, 1 = deceased

os_time

Overall survival time in months

pfs_status

Progression free survival status, 0 = progression free, 1 = progressed

pfs_time

Progression free survival time in months

Source

https://www.nature.com/articles/s43018-020-0096-5